Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023 By Sarah EllinwoodJune 2, 2023 Funding, Awards and Collaborations BCWorld Healthcare and ReGelTec Enter Exclusive Distribution Agreement for [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023 By Sarah EllinwoodMay 26, 2023 Funding, Awards and Collaborations Adaptive Phage Therapeutics Partners with Hebrew University, Hadassah Medical [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 24, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 28, 2023 Funding, Awards and Collaborations Quest Diagnostics Acquires Haystack [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 17, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 21, 2023 Funding, Awards and Collaborations OpGen Enters Into Distribution [….]
The JP Morgan Healthcare conference (JPM23) is running January 9-13, 2023, in San Francisco. It’s one of the biggest biotech conferences, possibly the biggest, with companies from all over the world coming (or attending virtually) to network with possible investors, present their companies’ progress and breakthrough, announce their annual financial and milestone guidance, and negotiate deals.
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB), in an oral presentation at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting favorable safety and preliminary efficacy of an IAP antagonist for the treatment of patients with CHB.